14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CNAT ranks #15895 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Conatus Pharmaceuticals Inc. Stock Forecast NASDAQ:CNAT

$0.48 (4.97%)

Volume: 287k

Closed: Dec 08, 2021

Hollow Logo Score: -3.809

Conatus Pharmaceuticals Inc. Stock Forecast

$0.48 (4.97%)

Volume: 287k

Closed: Dec 08, 2021

Score Hollow Logo -3.809
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 34 and the stock is currently not being overbought or oversold

High volatility in Conatus Pharmaceuticals Inc. stock price on Wednesday which ended trading at $0.48
(Updated on Dec 08, 2021)

Sell candidate since 2021-11-09 Loss -31.37%

The Conatus Pharmaceuticals Inc. stock price gained 4.97% on the last trading day (Wednesday, 8th Dec 2021), rising from $0.46 to $0.48. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 13.89% from a day low at $0.44 to a day high of $0.50. The price has fallen in 6 of the last 10 days and is down by -2.5% for this period. Volume fell on the last day by -113 thousand shares and in total, 287 thousand shares were bought and sold for approximately $137.75 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -39.81% during the next 3 months and, with a 90% probability hold a price between $0.25 and $0.36 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, December 06, 2021, and so far it has risen 13.16%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Conatus Pharmaceuticals Inc. stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $0.60. On a fall, the stock will find some support from the short-term average at $0.45. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.

Support, Risk & Stop-loss

On the downside, the stock finds support just below today's level from accumulated volume at $0.45 and $0.44. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Conatus Pharmaceuticals Inc. finds support just below today's level at $0.45. If this is broken, then the next support from accumulated volume will be at $0.44 and $0.42.

This stock may move very much during the day (volatility) and with periodic low trading volume this stock is considered to be "very high risk". During the last day, the stock moved $0.0607 between high and low, or 13.89%. For the last week the stock has had a daily average volatility of 11.41%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Conatus Pharmaceuticals Inc. stock A Buy?

Conatus Pharmaceuticals Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -3.809

Predicted Opening Price for Conatus Pharmaceuticals Inc. of Thursday, December 9, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 9, 2021 Current price
$0.47 $0.48 (Overvalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Volatility and Risk
Daily Average Volatility: 11.41 %
Overall Risk: Very High High Medium Low Very Low
11.41 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $0.51
Price: $0.48
Support: $0.45

CNAT Insider Trading Show all Trades



Last 100 transactions
Buy: 9 917 556 | Sell: 1 304 556 (Shares)
Date Action Amount Person Type
Jan 13, 2021 Buy 100 000 Daniels Moya Stock Option (right to buy)
Jan 13, 2021 Buy 112 000 Knudson Susan A. Stock Option (right to buy)
Jan 13, 2021 Buy 346 000 Pascoe Richard W Stock Option (right to buy)
Jan 13, 2021 Buy 95 000 Naughton Gail K Stock Option (right to buy)
Jan 13, 2021 Buy 90 000 Latterich Martin Stock Option (right to buy)
Show all Insider Trades


Last 100 transactions
Buy: 9 917 556 | Sell: 1 304 556 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 0.53 10.94 %
0.51 6.10 %
0.49 3.12 %
Current price: 0.48
Support 0.45 -6.55 %
0.43 -9.54 %
0.41 -14.37 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0.57 18.85 %
0.57 18.16 %
0.51 5.29 %
Current price 0.48
Support 0.45 -6.78%
0.44 -9.28%
0.42 -11.63%

Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE